Isocitrate Dehydrogenase Mutations in Glioma: From Basic Discovery to Therapeutics Development
Isocitrate dehydrogenase (IDH) is a key rate-limiting enzyme in the Krebs cycle that plays an important role in energy metabolism. In recent years, it has been found that IDH mutations are closely related to the occurrence and development of glioma, and it is a notable potential therapeutic target....
Main Authors: | Juan Huang, Jialong Yu, Lin Tu, Nanqu Huang, Hang Li, Yong Luo |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2019-06-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fonc.2019.00506/full |
Similar Items
-
Screening of Methylation Signature and Gene Functions Associated With the Subtypes of Isocitrate Dehydrogenase-Mutation Gliomas
by: XiaoYong Pan, et al.
Published: (2019-11-01) -
Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer Therapeutics
by: Danielle Golub, et al.
Published: (2019-05-01) -
Identification of Isocitrate Dehydrogenase 2 (IDH2) Mutation in Carotid Body Paraganglioma
by: Fengchao Lang, et al.
Published: (2021-09-01) -
IDH1/2 (isocitrate dehydrogenase 1/2) Mutations in Gliomas : genotype-Phenotype Correlation, Prognostic impact, and Response to Irradiation
by: Wang, Xiao Wei
Published: (2012) -
Multidimensional scaling of diffuse gliomas: application to the 2016 World Health Organization classification system with prognostically relevant molecular subtype discovery
by: Patrick J. Cimino, et al.
Published: (2017-05-01)